An observational study in Depression and Suicide Risk, sponsored by National Institute of Mental Health (NIMH). Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by National Institute of Mental Health (NIMH) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in Depression by National Institute of Mental Health (NIMH) — 11 open to participants now, 11 under way, none of them phase 3. Depression · National Institute of Mental Health (NIMH).
Among the 97 studies in Depression by National Institute of Mental Health (NIMH), this one is the 7th largest by planned enrollment of the 45 observational ones that give a count, is one of 4 that started in 2021, is one of 45 observational ones, and was the 92nd registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →11 of the 97 studies in Depression by National Institute of Mental Health (NIMH) are open now, in 1 country. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 18–70
National Institute of Mental Health (NIMH) · Sites in United States
Ages 18–120
National Institute of Mental Health (NIMH) · Sites in United States
Ages 18–70 · Healthy volunteers
National Institute of Mental Health (NIMH) · Sites in United States
Ages 18–70 · Healthy volunteers
National Institute of Mental Health (NIMH) · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 27 · Phase 3 3 · Phase 4 7
First in 1979; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 175 across 1,261 observational studies indexed under Depression.
Median enrollment 60 across the 50 interventional studies, 140 across the 45 observational. Of the 81 that completed or were terminated, 17 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Mental Health (NIMH) is the lead sponsor of 367 studies on the registry; 45 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 24 (96%) have results posted.
4 of the studies in Depression by National Institute of Mental Health (NIMH) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03065335National Institute of Mental Health (NIMH)Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder | 2027-01-01 |
| NCT03973268National Institute of Mental Health (NIMH)Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression | 2027-02-01 |
| NCT03388606National Institute of Mental Health (NIMH)Characterization and Treatment of Adolescent Depression | 2027-07-01 |
| NCT06511908National Institute of Mental Health (NIMH)Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 97 studies in Depression by National Institute of Mental Health (NIMH), from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background:
More than 12,000 people have taken part in research at the Experimental Therapeutics \& Pathophysiology Branch at the National Institute of Mental Health Intramural Program. This has led to advances in the treatment of depression, bipolar disorder, and suicide risk. Researchers want to follow up with this group to see if they continue to have mental health symptoms and receive psychiatric treatments.
Objective:
To learn the long-term impact of depression, bipolar disorder, and suicide risk.
Eligibility:
Adults ages 18 and older who signed consent for Protocol 01-M-0254 over a year ago.
Design:
This study has 2 phases: an online phase and a telephone phase. It has no in-person or face-to-face contact.
In Phase 1, participants will fill out online surveys. They will access the surveys through the study website. The questions will focus on their current thoughts and feelings. The surveys will also ask about their current treatments for their mental health symptoms. At the end of the surveys, they will be asked if they would like to take part in Phase 2. If so, they will mark yes. Phase 2 includes a phone interview. They will be contacted by email to schedule the interview.
In Phase 2, participants will be asked more in-depth questions about how they are feeling. They will also be asked which psychiatric medicines and treatments they have used since they left NIH.
In both phases, participants can skip any questions they do not want to answer.
The online surveys will take 30 minutes to complete. The phone interview will last 1-4 hours.
The information that participants give in this study may be linked to their other NIH research records.
Study Description: The proposal will leverage existing data on former participants with mood disorders collected in the Experimental Therapeutics and Pathophysiology Branch in order to identify predictors of long-term depressive symptoms, suicide attempts and ketamine utilization. The ETPB has collected a wealth of clinical, biologic, neuroimaging and sleep data on individuals with treatment resistant depression and bipolar disorder over the last 20 years. This study would re-contact these individuals for online and telephone assessment of current symptoms. We would then determine the ability of these clinical and biological measures to predict long-term outcomes. For individuals who do not participate in online or telephone data collection, we would like to identify incidence of premature death, including suicide, using linkage to data sources such as the National Death Index. We will also use this protocol for recruitment for in-person neurobiological studies and clinical trials of treatment resistant depression, bipolar disorder and suicide risk, both for ETPB and other branches of the NIMH IRP.
Objectives: The primary objective is to identify predictors of long-term treatment-resistant depression. The secondary and tertiary objectives are to identify predictors of long-term risk for suicide attempt and identify predictors of repeat use of ketamine, respectively
Endpoints:
Primary Endpoint: Score on Beck Depression Inventory
Secondary Endpoint: Self-reported suicide attempt after NIH study participation
Secondary Endpoint: Self-reported ketamine utilization after NIH study participation
Secondary Endpoint: Suicide death as reported by the National Death Index
Study Population: The sample size will be up to 1000 participants who previously signed consent into Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers and will include participants 18 years and older, any gender and health status.
Description of Sites/Facilities Enrolling Participants: The study will be conducted online through a secure study website. Data collection can also occur over the phone.
Study Duration: 1 year
Participant Duration: 20 minutes- 4 hours
This study involves re-contacting former participants of 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers for participation in this follow-up study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
EXCLUSION CRITERIA:
None.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals who previously signed consent for ETPB research as healthy volunteers
Individuals with mood disorders who previously signed consent for ETPB research
Score on Beck Depression Inventory (suicide item removed)
Rating of depression without assessment of suicidal ideation
Time frame: Follow-up assessment
Ketamine utilization at non-NIH facility
Participants will report whether they accessed ketamine/esketamine after leaving NIH
Time frame: Follow-up assessment
Self-reported suicide attempt
Self-reported suicide attempt since leaving NIH
Time frame: Follow-up assessment
Identify predictors of death by suicide
Death as reported by the National Death Index (NDI)
Time frame: Follow-up assessment
Plan to share: Yes — Clinical and demographic and biomarker participant data collected during the trial, after deidentification.
Supporting information: Statistical analysis plan
Time frame: Starting within 1 year of completion of the study
Access criteria: Branch Chief will review requests and access will need to be approved by the NIMH/DIRP SD and OCD NIMH and the NIH IIRB.
Started Aug 2021 (actual). Primary completion is estimated for Oct 2028, 85 months after the start.
Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 85 months is above that.
Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Mental Health (NIMH) →